Severity

A subset of Member States and areas monitors severe disease related to influenza virus infection by surveillance of 1) hospitalized laboratory-confirmed influenza cases in ICUs (12 Member States or areas), or other wards (8 Member States or areas), or 2) severe acute respiratory infection (SARI; 17 Member States or areas).

1.1) Hospitalized laboratory-confirmed influenza cases – ICUs

From week 21/2019 through week 32/2019, four countries (Czech Repulic, Ireland, Spain and Sweden) reported 7 laboratory-confirmed influenza cases in ICUs; 6 were influenza A and 1 was influenza B virus. The two influenza A viruses subtyped were A(H3N2).

1.2) Hospitalized laboratory-confirmed influenza cases – other wards

For week 21/2019 through week 32/2019, three countries (Czech Repulic, Ireland and Spain) reported 42 laboratory-confirmed influenza cases from other wards, of which 41 were influenza A and 1 was influenza B virus. The 10 influenza A viruses subtyped were A(H3N2). The majority (64%) of influenza cases reported were among individuals aged 65 years and older.

2. SARI surveillance

For weeks 21–32/2019, 10 579 SARI cases were reported by 8 Member States or areas. Of these cases, 518 specimens were tested for influenza viruses and 9 (1.7%) tested positive; 6 were type B and 3 were type A. All influenza A viruses were subtype A(H3N2).

Mortality monitoring

For week 32/2019, the EuroMOMO project received data from 20 countries or areas that were included in pooled analyses. Pooled estimates of all-cause mortality showed mortality levels within normal expected ranges for the participating countries. However, the Netherlands, and possibly other countries, saw a small increase in mortality in the past few weeks that could be related to the high temperatures experienced during the current summer season in Europe.